Renin-angiotensin aldosterone inhibitor use at hospital discharge among patients with moderate to severe acute kidney injury and its association with recurrent acute kidney injury and mortality.

Recurrent episodes of acute kidney injury (AKI) are common among AKI survivors. Renin-angiotensin aldosterone inhibitors (RAASi) are often indicated for these patients but may increase the risk for recurrent AKI. Here, we examined whether RAASi associates with a higher risk for recurrent AKI and mortality among survivors of moderate to severe AKI in a retrospective cohort of Veterans who survived Stage II or III AKI. The primary exposure was RAASi at hospital discharge and the primary endpoint was recurrent AKI within 12 months.

Source: Kidney International - September 7, 2020 Category: Urology & Nephrology Authors: Edward D. Siew, Sharidan K. Parr, Khaled Abdel-Kader, Amy M. Perkins, Robert A. Greevy, Andrew J. Vincz, Jason Denton, Otis D. Wilson, Adriana M. Hung, T. Alp Ikizler, Cassianne Robinson-Cohen, Michael E. Matheny Tags: clinical investigation Source Type: research